



ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009

March 2, 2009

ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the fourth quarter and year ended December 31, 2008 on Monday, March 9, 2009, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.

The conference call may be accessed by dialing 866-700-0161 for participants in the U.S. or Canada and 617-213-8832 for international callers (reference passcode 63914388). A telephone replay of the conference call may be accessed through March 23, 2009 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 11398116). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until March 23, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson's disease psychosis, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Director, Investor Relations

Thomas H. Aasen, Vice President and Chief Financial Officer

858-558-2871